Innate Pharma

YTD

ALL

Why Robinhood?

You can watch Innate Pharma and buy or sell other stocks, ETFs, and their options commission-free!

About IPHA

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62.

CEO

Jonathan Dickinson

CEOJonathan Dickinson

Employees

181

Employees181

Headquarters

Marseille, Provence-Alpes-Cote-dAzur

HeadquartersMarseille, Provence-Alpes-Cote-dAzur

Founded

1999

Founded1999

Employees

181

Employees181

IPHA Key Statistics

Market cap

182.15M

Market cap182.15M

Price-Earnings ratio

-3.11

Price-Earnings ratio-3.11

Dividend yield

—

Dividend yield—

Average volume

22.23K

Average volume22.23K

High today

$2.05

High today$2.05

Low today

$1.94

Low today$1.94

Open price

$1.96

Open price$1.96

Volume

13.72K

Volume13.72K

52 Week high

$3.51

52 Week high$3.51

52 Week low

$1.29

52 Week low$1.29

IPHA News

TipRanks 1d

Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating

Leerink Partners analyst Daina Graybosch downgraded the rating on Innate Pharma to a Hold today, setting a price target of $2.00. Elevate Your Investing Strateg...